Great West Life Assurance Co. Can Increases Position in Zimmer Biomet Holdings Inc (ZBH)

Great West Life Assurance Co. Can increased its stake in Zimmer Biomet Holdings Inc (NYSE:ZBH) by 22.0% in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 156,862 shares of the medical equipment provider’s stock after acquiring an additional 28,259 shares during the period. Great West Life Assurance Co. Can’s holdings in Zimmer Biomet were worth $19,986,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Lindbrook Capital LLC raised its stake in shares of Zimmer Biomet by 207.6% during the first quarter. Lindbrook Capital LLC now owns 203 shares of the medical equipment provider’s stock valued at $25,000 after acquiring an additional 137 shares during the last quarter. Motco raised its stake in shares of Zimmer Biomet by 86.2% during the first quarter. Motco now owns 216 shares of the medical equipment provider’s stock valued at $28,000 after acquiring an additional 100 shares during the last quarter. Doyle Wealth Management bought a new position in shares of Zimmer Biomet during the fourth quarter valued at about $41,000. Pinnacle Bank bought a new position in shares of Zimmer Biomet during the fourth quarter valued at about $45,000. Finally, Horan Capital Advisors LLC. bought a new position in shares of Zimmer Biomet during the first quarter valued at about $51,000. Institutional investors own 88.49% of the company’s stock.

Several brokerages have recently commented on ZBH. TheStreet raised shares of Zimmer Biomet from a “c” rating to a “b-” rating in a research note on Friday, April 26th. Cantor Fitzgerald set a $135.00 price objective on shares of Zimmer Biomet and gave the company a “buy” rating in a research note on Friday, April 26th. Needham & Company LLC raised shares of Zimmer Biomet from a “buy” rating to a “strong-buy” rating and upped their price objective for the company from $146.00 to $155.00 in a research note on Wednesday, April 24th. Barclays upped their price objective on shares of Zimmer Biomet from $113.00 to $117.00 and gave the company an “underweight” rating in a research note on Monday, April 15th. Finally, Zacks Investment Research downgraded shares of Zimmer Biomet from a “hold” rating to a “sell” rating in a research note on Saturday, April 13th. Four research analysts have rated the stock with a sell rating, eight have issued a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $130.19.

ZBH stock opened at $114.52 on Friday. Zimmer Biomet Holdings Inc has a 1 year low of $96.99 and a 1 year high of $134.55. The stock has a market capitalization of $23.45 billion, a P/E ratio of 14.99, a P/E/G ratio of 2.14 and a beta of 1.19. The company has a quick ratio of 0.97, a current ratio of 2.00 and a debt-to-equity ratio of 0.72.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings results on Friday, April 26th. The medical equipment provider reported $1.87 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.86 by $0.01. Zimmer Biomet had a negative net margin of 3.90% and a positive return on equity of 13.24%. The company had revenue of $1.98 billion during the quarter, compared to the consensus estimate of $1.97 billion. During the same period in the prior year, the firm earned $1.91 earnings per share. Zimmer Biomet’s revenue was down 2.1% on a year-over-year basis. On average, equities analysts anticipate that Zimmer Biomet Holdings Inc will post 7.81 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, April 30th. Shareholders of record on Friday, March 29th were issued a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 0.84%. The ex-dividend date was Thursday, March 28th. Zimmer Biomet’s dividend payout ratio (DPR) is presently 12.57%.

In other Zimmer Biomet news, Director Syed A. Jafry acquired 1,925 shares of the business’s stock in a transaction on Friday, March 1st. The shares were acquired at an average price of $125.52 per share, for a total transaction of $241,626.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.72% of the stock is currently owned by corporate insiders.

ILLEGAL ACTIVITY NOTICE: This news story was reported by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this news story on another domain, it was copied illegally and republished in violation of international copyright and trademark legislation. The legal version of this news story can be read at https://sportsperspectives.com/2019/05/26/great-west-life-assurance-co-can-increases-position-in-zimmer-biomet-holdings-inc-zbh.html.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental.

Recommended Story: How to find the components of the quick ratio

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings Inc (NYSE:ZBH).

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.